1. Home
  2. XBIO

as of 05-29-2026 10:33am EST

$3.10
$0.05
-1.45%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Founded: N/A Country:
United States
United States
Employees: 2 City: FRAMINGHAM
Market Cap: 7.2M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 10.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.90 - $13.93 Next Earning Date: 05-13-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 2.81% Revenue Growth (next year): -16.67%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: